“Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS”

In this paper, we report use of the Olink targeted proteomic platform to identify ~90 proteins that change pre-symptomatically, before ALS phenoconversion.

Using a small subset of these proteins, we were able to predict the timing of phenoconversion.

These findings are critical to future ALS prevention trials.